Can Avacta’s £16m fundraise extend its oncology momentum after 91% disease control rate?

Avacta Group plc (LSE: AVCT), a clinical-stage biopharmaceutical company developing peptide drug conjugate (PDC) oncology therapies through its proprietary pre|CISION platform, has raised approximately £16 million via a conditional oversubscribed placing. The new funding arrives at a critical juncture as Avacta progresses its lead candidate faridoxorubicin (AVA6000) through Phase 1b trials and prepares to initiate a new Phase Ia study for its next clinical asset, FAP-EXd (AVA6103). The company also presented robust clinical data at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, showing a disease control rate of 91 percent in salivary gland cancer patients treated with faridoxorubicin.

The placing was structured through the issuance of 25.39 million new shares at an issue price of 63 pence per share, representing a discount of approximately 8.7 percent to the closing market price of 69 pence on October 17, 2025. Zeus Capital Limited acted as sole bookrunner for the transaction. Following admission of the new shares, scheduled for November 3, Avacta’s enlarged issued share capital will rise to 436.4 million ordinary shares.

The raise has drawn fresh institutional interest into Avacta’s long-term pipeline while providing the necessary liquidity to satisfy near-term convertible bond obligations. It also allows the UK-based oncology-focused drugmaker to retain full ownership of its platform, extend its runway into the second half of 2026, and defer certain repayments tied to its convertible instrument, effectively restructuring its financial obligations without triggering immediate dilution.

How is the pre|CISION platform redefining chemotherapy delivery in oncology?

Avacta’s core value proposition rests on the pre|CISION® platform, a proprietary drug delivery technology that enables the targeted release of chemotherapy drugs within the tumor microenvironment. This approach repurposes traditional oncology agents such as doxorubicin by linking them to a cleavable peptide that renders the drug inactive systemically until it reaches tumor tissue. Once there, the peptide is enzymatically cleaved by fibroblast activation protein (FAP), a protein prevalent in tumor stroma but sparse in healthy tissue, thereby releasing the active chemotherapy payload only where it is needed.

This tumor-specific delivery mechanism is designed to minimize off-target toxicity while enabling higher dosing than would otherwise be feasible with conventional systemic chemotherapy. The result is a new class of peptide drug conjugates (PDCs) that retain the efficacy of traditional agents but with a superior safety profile and broader applicability across solid tumors.

At a mechanistic level, the pre|CISION approach leverages what is referred to as the bystander effect. Because not all tumor types express FAP within cancer cells themselves, the ability of released drug molecules to diffuse and affect nearby non-FAP-expressing cancer cells becomes essential. According to Avacta’s latest data, the platform achieves exactly that, offering the potential to extend its therapeutic impact even in tumor types with low or heterogeneous FAP expression.

What does the faridoxorubicin clinical data reveal about efficacy and safety?

The most recent clinical data presented at ESMO 2025 reinforces Avacta’s thesis. In a Phase 1a trial involving patients with salivary gland cancer and soft tissue sarcomas, faridoxorubicin (FAP-Dox, AVA6000) demonstrated a 91 percent disease control rate in the salivary gland cancer cohort. Perhaps even more compelling is that median progression-free survival has not yet been reached, despite a median follow-up period of 41 weeks, indicating potential durability in therapeutic response that exceeds standard benchmarks in this patient population.

Equally significant are the safety findings. Patients were dosed up to 385 mg/m²—four times the typical dose of conventional doxorubicin—and some received cumulative doses as high as 550 mg/m², a level at which severe cardiotoxicity would typically emerge. Yet, no severe cardiac adverse events were reported, even at these elevated levels. This marks a critical validation point for pre|CISION®’s ability to reduce cardiotoxicity, a major limiting factor in doxorubicin-based therapy.

Avacta’s chief executive officer, Christina Coughlin, described these findings as a breakthrough in tumor-specific delivery, pointing out that the platform appears to eliminate cardiac signals even at higher cumulative exposures. She further highlighted that efficacy was observed even in tumors without detectable FAP expression, strengthening the case for pre|CISION®’s bystander effect and reinforcing its platform potential across a wider range of tumor types.

How does the fundraise impact Avacta’s capital structure and clinical strategy?

The gross proceeds of approximately £16 million will be allocated toward advancing several key programs. These include the continuation of the faridoxorubicin Phase 1b trial, the planned IND submission and clinical initiation of FAP-EXd (AVA6103), and the further development of the AVA6207 dual payload program. The funds also provide working capital to cover general operations through late 2026.

In addition to extending the runway, the equity raise allows Avacta to fulfill its convertible bond obligations, particularly the quarterly repayment and interest due in October 2025. With the bond amendments announced earlier this year, the upcoming January and April 2026 repayments have now been deferred until October 2027. This restructuring reduces near-term financial pressure while maintaining strategic flexibility.

The bond’s conversion price has also been reset to 75 pence from the previous 88.72 pence. Although the revised terms introduce the possibility of future equity dilution, the structure includes safeguards that limit bondholder acceleration to one quarter per quarter, and only under specific conditions such as trial data publication or reaching a defined date.

What is the outlook for Avacta’s clinical pipeline in 2026?

Over the next 12 months, Avacta plans to initiate a Phase Ia trial of FAP-EXd (AVA6103), a second-generation PDC candidate with a novel linker payload architecture. This program is expected to enter the clinic in the first quarter of 2026, subject to regulatory clearance via an IND filing with the US Food and Drug Administration. Interest from potential partners has reportedly increased, but Avacta appears intent on retaining development control in the early stages.

In parallel, the company is building out its dual payload technology under the AVA6207 program. This platform seeks to combine two synergistic therapeutic agents in a single construct, broadening the functional scope of pre|CISION beyond mono-payload strategies. According to management commentary, this effort reflects the future direction of the platform, emphasizing both modularity and scalability.

Coughlin reiterated that the ability to advance these assets without surrendering equity or licensing rights represents a long-term strategic advantage, especially in a competitive landscape where early-stage biotechs often sell off promising assets prematurely.

How is the market reacting to Avacta’s clinical and financial milestones?

Avacta shares closed at 69.00 GBX on October 20, 2025, reflecting a flat performance for the day. However, the stock has gained more than 130 percent over the past three months, rising from lows of around 30 GBX in July to recent highs of 75.00 GBX. The current market capitalization stands at approximately £283.6 million.

Investor sentiment appears strongly aligned with recent trial data and the clarity of the company’s financing roadmap. The oversubscribed nature of the placement suggests robust institutional support, even at a modest discount to market price. Analysts suggest that Avacta’s decision to raise capital now, rather than entering risk-sharing partnerships prematurely, indicates a belief in future valuation inflection points.

The deferral of bond repayments and reset of conversion terms may act as a double-edged sword. On one hand, the extension reduces short-term pressure on the balance sheet. On the other, the lowered conversion price raises the specter of future dilution if share price momentum stalls or if data readouts do not meet expectations. Nevertheless, current sentiment skews bullish, especially among retail forums and UK-focused biotech investors.

What does this mean for investors watching the biotech and oncology sectors?

For investors tracking the evolution of targeted oncology platforms, Avacta is emerging as a bellwether of clinical-stage resilience. The company’s ability to deliver meaningful Phase 1 efficacy data, extend its capital runway, and retain control of its pipeline—all while deferring debt obligations—makes it one of the more strategic players on the AIM market.

If the pre|CISION platform continues to generate clean safety and durable efficacy data across tumor types, Avacta could position itself not just as a tech licensor but as a fully integrated oncology innovator. The platform’s demonstrated ability to work even in tumors lacking FAP expression broadens its total addressable market, potentially placing it on the radar of both large biopharma partners and acquisition-minded investors.

The coming months will be pivotal as the company approaches IND filings, additional trial milestones, and possibly strategic collaborations. For now, the fundraise and ESMO data suggest that Avacta is capitalized for a sustained push through the next leg of clinical development and value creation.

Key takeaways: What investors should know about Avacta’s equity raise and oncology trial momentum

• Avacta Group plc (LSE: AVCT) raised £16 million via an oversubscribed placing at 63 pence per share, offering a modest 8.7% discount to the previous close.
• The funding extends Avacta’s cash runway into the second half of 2026 and enables the company to advance faridoxorubicin (AVA6000), FAP-EXd (AVA6103), and the AVA6207 dual payload platform.
• Clinical data from the Phase 1a trial of faridoxorubicin demonstrated a 91% disease control rate in salivary gland cancer and no severe cardiac toxicity at high cumulative doses.
• Avacta confirmed that FAP-EXd is on track to enter clinical trials in Q1 2026, pending FDA IND approval.
• Convertible bond repayments due in January and April 2026 have been deferred until October 2027, easing near-term balance sheet pressures.
• The bond conversion price was reset from 88.72p to 75p, raising the risk of dilution but giving Avacta flexibility to manage repayments based on future trial milestones.
• CEO Christina Coughlin emphasized the company’s ability to retain full ownership of its pre|CISION pipeline, avoiding early licensing or M&A dilution.
• Shares in Avacta have more than doubled since July 2025, reflecting positive investor sentiment following trial results and the strategic fundraise.
• Analysts view the combination of trial momentum, platform versatility, and financial runway as a compelling setup for potential re-rating through 2026 milestones.